ReviewNature reviews. Rheumatology2020
Fibroblast growth factor signalling in osteoarthritis and cartilage repair.
Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 174 citations in OpenAlex.
- Materialogenetics: an emerging and promising framework for cell-specific genetic manipulation.Bioactive materials · 2026Article
- In situ-built chemo-electroactive hydrogel incorporating Mg-based hydrogen generators for osteoarthritis therapy.Materials today. Bio · 2026Article
- FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.Blood · 2026Article
- Smart functionalized cartilage repair microspheres: Concepts and applications.Materials today. Bio · 2026Review
- Light-Inducible Activation of FGFR3 Facilitates Chondrocyte Maturation.Cell proliferation · 2026Article
- Scalable Isolation of Human Umbilical Cord MSC-Derived Exosomes and Their Therapeutic Potential in Osteoarthritis.Bioengineering (Basel, Switzerland) · 2026Article
- Transcriptome analysis in osteoarthritis primary tissues identifies high-confidence effector genes.Nature communications · 2026Article
- Abnormal Stress Reduced miR-330 Supplementation Alleviates Osteoarthritis Progression by Suppressing Osteochondral Catabolism.Aging cell · 2026Article
- Bioinspired scaffold recapitulating chondrogenic ontogeny and microenvironment for functional cartilage regeneration.Bioactive materials · 2026Article
- FGF family in health and disease.Molecular biomedicine · 2026Review
- Ectodysplasin-A (EDA) Signaling Cross-Talk in Skeletogenesis.Calcified tissue international · 2026Review
- A damaging mutation in COL6A3 alters the mechanobiologic response of chondrocytes derived from human induced pluripotent stem cells.Stem cell research & therapy · 2026Article
- A Functional Shift of IGFBP3 in Osteoarthritis: From Cartilage Protection to Disease Promotion.Journal of inflammation research · 2026Review
- Nanotherapeutic Strategies for Osteoarthritis: Targeting Aging, Metabolism and Inflammation.International journal of nanomedicine · 2026Review
- Association between cellular characteristics and clinical outcomes following autologous micro-fragmented adipose tissue injection for knee osteoarthritis.Frontiers in bioengineering and biotechnology · 2026Article
- Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting.Frontiers in immunology · 2026Review
- Biologic and regenerative strategies for osteoarthritis: advances in MSC, exosome, and PRP based therapies.Frontiers in pharmacology · 2026Review
- FGF2-regulated Osteogenic Differentiation of Human Bone Marrow Stromal Cells.Current stem cell research & therapy · 2026Article
- Intermittent intra-articular delivery of FGF8b enhances cartilage homeostasis and attenuates osteoarthritis progression.Journal of orthopaedic translation · 2026Article
- The association of serum uric acid with severity and prognosis of patients with diabetic foot ulcers.Frontiers in endocrinology · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulated fibroblast growth factor (FGF) signalling is a prerequisite for the correct development and homeostasis of articular cartilage, as evidenced by the fact that aberrant FGF signalling contributes to the maldevelopment of joints and to the onset and progression of osteoarthritis. Of the four FGF receptors (FGFRs 1-4), FGFR1 and FGFR3 are strongly implicated in osteoarthritis, and FGFR1 antagonists, as well as agonists of FGFR3, have shown therapeutic efficacy in mouse models of spontaneous and surgically induced osteoarthritis. FGF18, a high affinity ligand for FGFR3, is the only FGF-based drug currently in clinical trials for osteoarthritis. This Review covers the latest advances in our understanding of the molecular mechanisms that regulate FGF signalling during normal joint development and in the pathogenesis of osteoarthritis. Strategies for FGF signalling-based treatment of osteoarthritis and for cartilage repair in animal models and clinical trials are also introduced. An improved understanding of FGF signalling from a structural biology perspective, and of its roles in skeletal development and diseases, could unlock new avenues for discovery of modulators of FGF signalling that can slow or stop the progression of osteoarthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.